Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts

Nina Kaludercic1, Andrea Carpi, Takahiro Nagayama

  • 11 Neuroscience Institute , National Research Council of Italy, Padova, Italy .

Abstract

Insights

Monoamine oxidase-B (MAO-B) contributes to heart failure by impairing mitochondrial function and increasing oxidative stress. Inhibiting MAO-B preserves cardiac structure and function during hemodynamic stress.

Area of Science:

  • Biochemistry
  • Cardiovascular Biology
  • Mitochondrial Biology

Background:

  • Monoamine oxidases (MAOs) are key enzymes in neurotransmitter metabolism.
  • MAO-A is implicated in heart failure through norepinephrine catabolism and oxidative stress.
  • The role of MAO-B in cardiac disease and its direct impact on mitochondrial function remain unclear.

Purpose of the Study:

  • To investigate the role of MAO-B in the pathogenesis of heart failure.
  • To determine if MAO activation directly affects mitochondrial function in the heart.

Main Methods:

  • Utilized a mouse model of pressure overload (transverse aortic constriction, TAC).
  • Compared wild-type mice with MAO-B knockout mice (MAO-B(-/-)).
  • Assessed cardiac structure, function, oxidative stress, and mitochondrial parameters in cardiomyocytes.

Main Results:

  • TAC induced cardiac dysfunction and remodeling in wild-type mice but not in MAO-B(-/-) mice.
  • MAO-B deficiency preserved left ventricular function and concentric hypertrophy.
  • MAO activation in cardiomyocytes reduced mitochondrial membrane potential and triggered ATP hydrolysis, effects reversed by MAO-B inhibition or aldehyde dehydrogenase 2 activation.

Conclusions:

  • Enhanced MAO-B activity is a significant factor in cardiac dysfunction under hemodynamic stress.
  • MAO-B contributes to heart failure by increasing oxidative stress and impairing aldehyde metabolism.
  • These factors adversely affect mitochondrial morphology and function, leading to cardiac damage.

Related Concept Videos

Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...